Review reveals expanding therapeutic options across localized and advanced bladder cancer stages, highlighting clinical integration of immune checkpoint inhibitors and antibody-drug conjugates.
Improved understanding of the molecular biology and genetics of bladder cancer has evolved the way localized and advanced disease is diagnosed and treated. While intravesical BCG has remained the mainstay of therapy for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for muscle-invasive and advanced disease has expanded to include immunotherapy with checkpoint inhibition, targeted therapies, and antibody-drug conjugates.
No takes yet. Share an insight, caveat, or question.
Lenis et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: